Vitamin D has been one of the best nutritional interventions for healthy aging. Various observational studies have demonstrated that older adults that have lower blood levels of vitamin D may be at greater risk for muscle weakness, slower walking pace, poor balance, and falls.
Consequently, vitamin D supplementation was made widely popular as a potential means of preserving muscle and its associated functions in aging. Many researchers believed, if we could establish adequate levels of Vitamin D status, we could possibly prevent sarcopenia (muscle loss due to normal aging). However, when this hypothesis was tested with some of the largest randomized controlled trials ever performed, the outcomes did not support this long-held belief.
The Mega-Trials: Putting Vitamin D to the Test
To assess if vitamin D supplementation could independently prevent the decline of muscle mass due to normal aging, three major trials were initiated with over 49,000 participants from around the world.
The VITAL Trial (United States)
The first of these trials was the Vitamin D and Omega-3 Trial (VITAL) of which Dr. JoAnn Manson and her colleagues had over 25,871 participants (men aged >50; women aged >55). All participants received 2000 IU/day of vitamin D3 (for an average of 5.3 years follow-up).
Key Findings
The study showed no statistically significant differences in total lean mass, muscle strength, physical performance, or any of the frailty outcome measures compared to placebo.
The D-Health Trial (Australia)
D-Health Study: Dr. Rachel Neale conducted the study with 21,315 participants aged 60-84 for nearly five years.
Key Findings
A monthly oral dose of 60,000 IU of Vitamin D₃ produced no statistically significant effects on frailty or improvement in musculoskeletal function.
The DO-HEALTH Trial (Europe)
DO-HEALTH Study: Dr. Heike Bischoff-Ferrari ran this five-country study of 2,157 people aged 70 and older with a daily supplement of 2,000 IUs of Vitamin D₃ for three years measuring changes in physical performance.
Key Findings
Vitamin D alone produced no statistically substantial improvement in walking distance, muscle power, or overall physical functioning. The combination of Vitamin D plus exercise and nutritional support was more likely to produce improvement.
The Threshold Hypothesis
As data from three major trials grew, a definition related to how biologically effective a nutrient is was coined: the Threshold Hypothesis. Serum concentrations of 25(OH)D below the threshold of 20 ng/mL (50 nmol/L) were characterized as deficient.
Conversely, serum concentrations of 25(OH)D above 20 ng/mL were characterized as sufficient.
Clinical Implications
The majority of participants in VITAL, D-Health, and DO-HEALTH encompassed baseline serum levels of Vitamin D within the range of 25–31 ng/mL.
Due to the closed state of their physiological needs and the lack of additional measurable muscle benefit provided through supplementation, the authors conclude that correcting deficiency is beneficial; whereas, supplementation beyond sufficient levels is not likely to offer significant protection from the potential consequences associated with sarcopenia.
These results produce clear evidence that a single nutrient alone, in this case Vitamin D, has no significant impact on preventing muscle loss due to natural aging. Furthermore, the authors make it evident that correcting deficiency is fundamentally different from enhancing performance above what would occur through the normal aging process.
The primary effect of Vitamin D appears to be resolving deficiencies that exist, rather than providing additional effects once adequate concentrations of the nutrient are achieved.
The DO-HEALTH trial further suggests that combining Vitamin D with both exercise and nutrition may have the greatest impact on preventing sarcopenia since it demonstrates how multifactorial (due to many factors) this condition is through factors affecting nutrient absorption, physical activity (hormonal changes, chronic inflammation) and nutrition itself.
A Shift in Clinical Practice
The strength of this data has had a profound impact on developing recommendations for medicine today.
A major shift occurred with the introduction of the 2024 Endocrine Society Clinical Practice Guidelines, and now routine and universal supplementation is not recommended and supplement use should be only for those most likely to benefit from the correction of Vitamin D deficiency.
Conclusion
Historically, it was assumed that everyone supplemented with Vitamin D would improve their musculoskeletal (MSK) health.
Therefore, it has become clear that these landmark studies (VITAL=25871, D-Health=21315, and DO-HEALTH=2157) have significantly changed the way we understand Vitamin D’s role in muscle health. There continues to be a need for adequate vitamin D levels; however, the landmark studies are indicating that even if one is vitamin D replete there will still be a reduction of muscle mass unless a more comprehensive approach is taken to preserve/maintain muscle strength combining the treatment for those found to have low levels of Vitamin D, a diet high enough in protein, and regular strength (resistance) training.
Rather than serving as a standalone solution, Vitamin D appears to be one important piece of a much larger muscle-health puzzle.
References
- Manson JE, et al. The Vitamin D and Omega-3 Trial (VITAL). New England Journal of Medicine.
- Neale RE, et al. The D-Health Trial. The Lancet Diabetes & Endocrinology.
- Bischoff-Ferrari HA, et al. The DO-HEALTH Randomized Clinical Trial. JAMA.
- Endocrine Society. Vitamin D for the Prevention of Disease: Clinical Practice Guideline. 2024.
- EWGSOP2. Sarcopenia: Revised European Consensus on Definition and Diagnosis. Age and Ageing. 2019.